Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02256917 · ClinicalTrials.gov registry record · Phase 3
Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
A Phase 3 study, sponsored by Octapharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT02256917 is a Phase 3 study that has completed, run by Octapharma. The registered enrollment target is 58 participants.
The verdict
NCT02256917, a Phase 3 study, has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The rationale of this study is to further fine-tune and individualize prophylactic treatment of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above 1% between doses. Because trough FVIII levels are likely to be important predictors of the efficacy of prophylaxis, the focus of this study is on pharmacokinetic (PK) data.
Interventions
- BIOLOGICAL Human cl rhFVIII
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02256917
The ClinicalTrials.gov registry entry for NCT02256917 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Octapharma, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human cl rhFVIII is the first listed.
NCT02256917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02256917 about?
NCT02256917 is a clinical study titled "Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A". The rationale of this study is to further fine-tune and individualize prophylactic treatment of patients with severe Haemophilia A with the goal of keeping the trough FVIII level above 1% between doses. Because trough FVIII levels are likely to be important predictors of the efficacy of prophylaxis,...
What is the current status of trial NCT02256917?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2015-05. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02256917?
The interventions under investigation include: Human cl rhFVIII (BIOLOGICAL).
Who is sponsoring clinical trial NCT02256917?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.